Cargando…

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

The competing roles of various next-generation ALK TKIs in the first and second line treatment setting of advanced ALK+ NSCLC were based on many phase 3 clinical trials in both the first-line and crizotinib-refractory settings. The approval of all next-generation ALK TKIs was first in the crizotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Alexandria T M, Ou, Saihong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292622/
https://www.ncbi.nlm.nih.gov/pubmed/37377783
http://dx.doi.org/10.2147/LCTT.S413091

Ejemplares similares